Avinger (AVGR) Competitors $0.47 0.00 (0.00%) As of 06/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVGR vs. PSTV, BLAC, AEMD, QNRX, CHEK, AMIX, HSCS, NUWE, GCTK, and TIVCShould you be buying Avinger stock or one of its competitors? The main competitors of Avinger include Plus Therapeutics (PSTV), Bellevue Life Sciences Acquisition (BLAC), Aethlon Medical (AEMD), Quoin Pharmaceuticals (QNRX), Check-Cap (CHEK), Autonomix Medical (AMIX), Heart Test Laboratories (HSCS), Nuwellis (NUWE), GlucoTrack (GCTK), and Tivic Health Systems (TIVC). These companies are all part of the "medical equipment" industry. Avinger vs. Its Competitors Plus Therapeutics Bellevue Life Sciences Acquisition Aethlon Medical Quoin Pharmaceuticals Check-Cap Autonomix Medical Heart Test Laboratories Nuwellis GlucoTrack Tivic Health Systems Avinger (NASDAQ:AVGR) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Which has more risk & volatility, AVGR or PSTV? Avinger has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Do insiders and institutionals have more ownership in AVGR or PSTV? 18.3% of Avinger shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 42.8% of Avinger shares are held by insiders. Comparatively, 3.8% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor AVGR or PSTV? Avinger received 320 more outperform votes than Plus Therapeutics when rated by MarketBeat users. However, 62.93% of users gave Plus Therapeutics an outperform vote while only 55.67% of users gave Avinger an outperform vote. CompanyUnderperformOutperformAvingerOutperform Votes39355.67% Underperform Votes31344.33% Plus TherapeuticsOutperform Votes7362.93% Underperform Votes4337.07% Is AVGR or PSTV more profitable? Plus Therapeutics has a net margin of -225.07% compared to Avinger's net margin of -261.06%. Plus Therapeutics' return on equity of 0.00% beat Avinger's return on equity.Company Net Margins Return on Equity Return on Assets Avinger-261.06% -5,527.11% -123.25% Plus Therapeutics -225.07%N/A -154.56% Does the media favor AVGR or PSTV? In the previous week, Plus Therapeutics had 3 more articles in the media than Avinger. MarketBeat recorded 3 mentions for Plus Therapeutics and 0 mentions for Avinger. Plus Therapeutics' average media sentiment score of 0.91 beat Avinger's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Avinger Neutral Plus Therapeutics Positive Do analysts rate AVGR or PSTV? Plus Therapeutics has a consensus target price of $11.67, indicating a potential upside of 3,240.97%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Avinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avinger 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Plus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings and valuation, AVGR or PSTV? Plus Therapeutics has lower revenue, but higher earnings than Avinger. Plus Therapeutics is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvinger$7.26M0.22-$18.32M-$11.06-0.04Plus Therapeutics$4.91M1.21-$13.32M-$2.94-0.12 SummaryPlus Therapeutics beats Avinger on 11 of the 18 factors compared between the two stocks. Get Avinger News Delivered to You Automatically Sign up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVGR vs. The Competition Export to ExcelMetricAvingerSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57M$4.38B$5.61B$8.62BDividend YieldN/A42.67%5.28%4.17%P/E Ratio-0.0428.2927.1419.96Price / Sales0.2270.02411.83157.63Price / CashN/A51.0838.2534.64Price / Book-0.105.827.064.69Net Income-$18.32M$67.63M$3.23B$248.14M7 Day PerformanceN/A0.36%2.67%2.39%1 Month PerformanceN/A15.07%8.82%6.05%1 Year Performance-70.56%17.95%31.44%13.60% Avinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVGRAvingerN/A$0.47flatN/AN/A$1.57M$7.26M-0.0470PSTVPlus Therapeutics2.3421 of 5 stars$0.37+28.2%$11.50+3,027.5%-84.8%$6.25M$4.91M-0.1520Short Interest ↓Gap UpHigh Trading VolumeBLACBellevue Life Sciences AcquisitionN/A$1.45+18.9%N/A-84.5%$5.86MN/A0.00N/AGap UpHigh Trading VolumeAEMDAethlon Medical3.1544 of 5 stars$0.36-3.9%$7.00+1,847.1%-54.1%$5.77M$570K-0.2310News CoverageShort Interest ↓QNRXQuoin Pharmaceuticals1.5459 of 5 stars$8.74+2.5%N/A-67.2%$5.14MN/A-2.164Short Interest ↓CHEKCheck-Cap1.1947 of 5 stars$0.80-1.9%N/A-63.8%$4.69MN/A-0.2780Positive NewsShort Interest ↓Gap DownAMIXAutonomix Medical2.7044 of 5 stars$1.65+1.5%$16.50+900.0%-93.9%$4.06MN/A-0.131Short Interest ↑Gap UpHSCSHeart Test Laboratories2.6912 of 5 stars$3.69+4.5%$13.00+252.3%-32.3%$3.99M$14.70K-0.4710Short Interest ↑NUWENuwellis3.0852 of 5 stars$0.85-1.7%$17.00+1,911.8%-94.7%$3.70M$8.79M-0.0170Gap DownGCTKGlucoTrack1.6356 of 5 stars$0.13-1.9%N/A-99.7%$3.65MN/A0.005Short Interest ↓Gap DownTIVCTivic Health Systems0.5011 of 5 stars$4.12-0.2%N/A-44.1%$3.62M$516K0.0010Positive News Related Companies and Tools Related Companies Plus Therapeutics Alternatives Bellevue Life Sciences Acquisition Alternatives Aethlon Medical Alternatives Quoin Pharmaceuticals Alternatives Check-Cap Alternatives Autonomix Medical Alternatives Heart Test Laboratories Alternatives Nuwellis Alternatives GlucoTrack Alternatives Tivic Health Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVGR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVGR Stock Free AVGR Stock Alerts